Phase 3 Lung Cancer Trial, Recruiting NCT02448992 Sponsor: Chang Gung Memorial Hospital Condition: Lung Cancer
Back to Lung Cancer

Phase 3 Lung Cancer Trial, Recruiting

NCT02448992
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been clinically diagnosed with non-small cell lung cancer (NSCLC)
  • People aged 18 or older who have had surgery to remove the cancer and where laboratory testing of the removed tissue confirmed that the cancer had spread to nearby lymph nodes
  • People who are able to receive platinum-based chemotherapy as part of their treatment
  • People who are in reasonably good general health, as measured by standard medical scoring tools (confirm with trial site for exact score requirements)
  • People who are sufficiently proficient in the Mandarin language

Who may not be able to join:

  • People who have previously had radiation treatment to the brain
  • People who have another active cancer diagnosis, other than a specific type of minor skin cancer (basal cell carcinoma) or a very early-stage cervical condition (cervical carcinoma in situ)
  • People whose scans show that the cancer has spread to the brain
  • People with clinical signs that the cancer has spread to other parts of the body outside the brain
  • People who have had an allergic reaction to the contrast dye used in MRI scans
  • People with serious medical or mental health conditions

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Chi-Cheng Yang, Ph.D., Chang Gung University

Phone: 886-988378478

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Registry
ClinicalTrials.gov
Start date
1 August 2015
Est. completion
31 December 2026

Where this trial is recruiting

🇹🇼 Taiwan

Primary endpoints

time to the development of brain metastasis/metastases (BM), irrespective of the absence of active neurological symptoms

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov